New drug targets rare nerve tumors in people with specific gene loss
NCT ID NCT07549022
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called BMS-986504 in people with a rare cancer called malignant peripheral nerve sheath tumor (MPNST) that cannot be removed by surgery. Only people whose tumors are missing a gene called MTAP can join. The drug is taken daily by mouth, and the study will check if it can shrink tumors or slow the cancer. About 17 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMS-986504 (an experimental drug taken by mouth)
What this could lead to
If it works, this could offer a new treatment option for people with MPNST whose tumors have a specific genetic change (MTAP deletion).
What could go wrong
This is a very early, small trial (17 people) testing an experimental drug. It may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPNST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact